ArcherDX and UCL to Present Data from their Collaboration at the 2020 AACR Virtual Annual Meeting https://archerdx.com/archerdx-and-ucl-to-present-data-from-their-collaboration-at-the-2020-aacr-virtual-annual-meeting/

ArcherDX and UCL to Present Data from their Collaboration at the 2020 AACR Virtual Annual Meeting BOULDER, Colo., April 15, 2020 /PRNewswire/ — ArcherDX, Inc., […]
ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan https://archerdx.com/archerdx-receives-approval-for-archermet-companion-diagnostic-for-tepmetko-tepotinib-in-advanced-non-small-cell-lung-cancer-in-japan/

ArcherDX Receives Approval for Archer®MET Companion Diagnostic for TEPMETKO® (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan BOULDER, Colo., March 25, 2020/PRNewswire/ — ArcherDX, […]
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device https://archerdx.com/archerdx-personalized-cancer-monitoring-pcm-technology-designated-by-fda-as-breakthrough-device/

ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device First Surveillance Tests Designed to Enable Community Hospitals and Labs to Deliver Rapid, […]
ArcherDX to Present at 38th Annual J.P. Morgan Healthcare Conference https://archerdx.com/archerdx-to-present-at-38th-annual-j-p-morgan-healthcare-conference/

ArcherDX to Present at 38th Annual J.P. Morgan Healthcare Conference BOULDER, Colo., Jan. 8, 2020 /PRNewswire/ — ArcherDX, Inc., a molecular diagnostics company dedicated to […]
ArcherDX Appoints Mark Massaro Chief Financial Officer https://archerdx.com/archerdx-appoints-mark-massaro-chief-financial-officer/

ArcherDX Appoints Mark Massaro Chief Financial Officer BOULDER, Colo., Jan. 7, 2020 /PRNewswire/ — ArcherDX, Inc., a molecular diagnostics company developing breakthrough solutions to advance […]
ArcherDX Announces Close of $55 Million Series C Financing https://archerdx.com/archerdx-announces-close-of-55-million-series-c-financing/

ArcherDX Announces Close of $55 Million Series C Financing Proceeds to Support Registration and Launch of STRATAFIDE™ Pan-Solid Tumor Companion Diagnostic (CDx) and Development of […]
ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests https://archerdx.com/archerdx-announces-partnership-with-illumina-to-develop-in-vitro-diagnostic-tests/

ArcherDX Announces Partnership with Illumina to Develop In-Vitro Diagnostic Tests Partnership Expands Physician Access to Clinical Testing that May be Performed in Local Laboratories for […]
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration https://archerdx.com/archerdx-and-ayala-pharmaceuticals-announce-strategic-companion-diagnostic-collaboration/

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration Enabling Genomically Defined Treatments for Underserved Cancers BOULDER, Colo., July 8, 2019 /PRNewswire/ — ArcherDX, Inc., […]
ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio https://archerdx.com/archerdx-inc-announces-close-of-60m-financing-to-advance-companion-diagnostic-and-minimal-residual-disease-monitoring-product-portfolio-2/

ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/– ArcherDX, […]
ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio https://archerdx.com/archerdx-inc-announces-close-of-60m-financing-to-advance-companion-diagnostic-and-minimal-residual-disease-monitoring-product-portfolio/

ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/– ArcherDX, […]